GeneMatrix Inc (109820) - Total Assets
Based on the latest financial reports, GeneMatrix Inc (109820) holds total assets worth ₩28.03 Billion KRW (≈ $19.00 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of GeneMatrix Inc to assess how comfortably operating cash covers total debt obligations.
GeneMatrix Inc - Total Assets Trend (2011–2024)
This chart illustrates how GeneMatrix Inc's total assets have evolved over time, based on quarterly financial data. See 109820 net assets for net asset value and shareholders' equity analysis.
GeneMatrix Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
GeneMatrix Inc's total assets of ₩28.03 Billion consist of 68.8% current assets and 31.2% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩1.82 Billion | 0.0% |
| Accounts Receivable | ₩2.32 Billion | 8.2% |
| Inventory | ₩3.00 Billion | 10.5% |
| Property, Plant & Equipment | ₩6.01 Billion | 21.1% |
| Intangible Assets | ₩61.22 Million | 0.2% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how GeneMatrix Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see GeneMatrix Inc (109820) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GeneMatrix Inc's current assets represent 68.8% of total assets in 2024, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, down from 16.2% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 16.0% in 2011.
- Asset Diversification: The largest asset category is property, plant & equipment at 21.1% of total assets.
GeneMatrix Inc Competitors by Total Assets
Key competitors of GeneMatrix Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Shanghai Labway Clinical Laboratory Co Ltd
SHE:301060
|
China | CN¥2.35 Billion |
|
Ningbo MedicalSystem Biotechnology Co Ltd
SHE:300439
|
China | CN¥3.66 Billion |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
|
INIFY LABORATORIES AB
F:WY60
|
Germany | €204.64 Million |
|
Check Cap Ltd
NASDAQ:CHEK
|
USA | $377.00K |
GeneMatrix Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.26 | 4.45 | 4.67 |
| Quick Ratio | 3.69 | 3.81 | 3.69 |
| Cash Ratio | 0.00 | 0.37 | 0.00 |
| Working Capital | ₩15.29 Billion | ₩14.69 Billion | ₩14.98 Billion |
GeneMatrix Inc - Advanced Valuation Insights
This section examines the relationship between GeneMatrix Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.69 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -9.2% |
| Total Assets | ₩28.46 Billion |
| Market Capitalization | $19.55 Million USD |
Valuation Analysis
Below Book Valuation: The market values GeneMatrix Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: GeneMatrix Inc's assets decreased by 9.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for GeneMatrix Inc (2011–2024)
The table below shows the annual total assets of GeneMatrix Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩28.46 Billion ≈ $19.29 Million |
-9.24% |
| 2023-12-31 | ₩31.35 Billion ≈ $21.25 Million |
-1.72% |
| 2022-12-31 | ₩31.90 Billion ≈ $21.62 Million |
-19.30% |
| 2021-12-31 | ₩39.53 Billion ≈ $26.79 Million |
+3.57% |
| 2020-12-31 | ₩38.17 Billion ≈ $25.87 Million |
+34.13% |
| 2019-12-31 | ₩28.46 Billion ≈ $19.28 Million |
-9.72% |
| 2018-12-31 | ₩31.52 Billion ≈ $21.36 Million |
+77.64% |
| 2017-12-31 | ₩17.74 Billion ≈ $12.02 Million |
-8.23% |
| 2016-12-31 | ₩19.33 Billion ≈ $13.10 Million |
-6.97% |
| 2015-12-31 | ₩20.78 Billion ≈ $14.08 Million |
+21.88% |
| 2014-12-31 | ₩17.05 Billion ≈ $11.55 Million |
-13.35% |
| 2013-12-31 | ₩19.68 Billion ≈ $13.33 Million |
-3.29% |
| 2012-12-31 | ₩20.35 Billion ≈ $13.79 Million |
-10.05% |
| 2011-12-31 | ₩22.62 Billion ≈ $15.33 Million |
-- |
About GeneMatrix Inc
GeneMatrix Inc. develops diagnostic products for various diseases in the field of molecular diagnostics. The company offers products for hepatitis B, hepatitis C, cervical cancer, sexually transmitted infections, respiratory infections, and gastrointestinal infections; vaccines for preventing various diseases; and new natural pharmaceutical materials for health enhancement and treatment. It also … Read more